569 related articles for article (PubMed ID: 31197526)
1. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
2. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
4. Serial Measurements of Left Ventricular Systolic and Diastolic Function by Cardiac Magnetic Resonance Imaging in Patients with Early Stage Breast Cancer on Trastuzumab.
Song L; Brezden-Masley C; Ramanan V; Ghugre N; Barfett JJ; Chan KKW; Haq R; Petrella T; Dhir V; Jimenez-Juan L; Chacko BR; Kotha V; Connelly KA; Yan AT
Am J Cardiol; 2019 Apr; 123(7):1173-1179. PubMed ID: 30683420
[TBL] [Abstract][Full Text] [Related]
5. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
[TBL] [Abstract][Full Text] [Related]
6. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.
Huang H; Nijjar PS; Misialek JR; Blaes A; Derrico NP; Kazmirczak F; Klem I; Farzaneh-Far A; Shenoy C
J Cardiovasc Magn Reson; 2017 Mar; 19(1):34. PubMed ID: 28335788
[TBL] [Abstract][Full Text] [Related]
7. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging.
Walker J; Bhullar N; Fallah-Rad N; Lytwyn M; Golian M; Fang T; Summers AR; Singal PK; Barac I; Kirkpatrick ID; Jassal DS
J Clin Oncol; 2010 Jul; 28(21):3429-36. PubMed ID: 20530277
[TBL] [Abstract][Full Text] [Related]
8. Myocardial strain imaging by cardiac magnetic resonance for detection of subclinical myocardial dysfunction in breast cancer patients receiving trastuzumab and chemotherapy.
Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Chow CM; Thavendiranathan D; Haq R; Barfett JJ; Petrella TM; Connelly KA; Yan AT
Int J Cardiol; 2018 Jun; 261():228-233. PubMed ID: 29555336
[TBL] [Abstract][Full Text] [Related]
9. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
10. Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab.
Bergamini C; Niro L; Springhetti P; Ferri L; Trento L; Minnucci I; Maffeis C; Tafciu E; Rossi A; Fiorio E; Benfari G; Ribichini F
Cardiovasc Toxicol; 2024 Jun; 24(6):550-562. PubMed ID: 38696070
[TBL] [Abstract][Full Text] [Related]
11. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
Goel S; Liu J; Guo H; Barry W; Bell R; Murray B; Lynch J; Bastick P; Chantrill L; Kiely BE; Abdi E; Rutovitz J; Asghari R; Sullivan A; Harrison M; Kohonen-Corish M; Beith J
JACC Heart Fail; 2019 Sep; 7(9):795-804. PubMed ID: 31401102
[TBL] [Abstract][Full Text] [Related]
12. Does diastolic dysfunction precede systolic dysfunction in trastuzumab-induced cardiotoxicity? Assessment with multigated radionuclide angiography (MUGA).
Reuvekamp EJ; Bulten BF; Nieuwenhuis AA; Meekes MR; de Haan AF; Tol J; Maas AH; Elias-Smale SE; de Geus-Oei LF
J Nucl Cardiol; 2016 Aug; 23(4):824-32. PubMed ID: 26048264
[TBL] [Abstract][Full Text] [Related]
13. Automated assessments of circumferential strain from cine CMR correlate with LVEF declines in cancer patients early after receipt of cardio-toxic chemotherapy.
Jolly MP; Jordan JH; Meléndez GC; McNeal GR; D'Agostino RB; Hundley WG
J Cardiovasc Magn Reson; 2017 Aug; 19(1):59. PubMed ID: 28768517
[TBL] [Abstract][Full Text] [Related]
14. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy.
Zardavas D; Suter TM; Van Veldhuisen DJ; Steinseifer J; Noe J; Lauer S; Al-Sakaff N; Piccart-Gebhart MJ; de Azambuja E
J Clin Oncol; 2017 Mar; 35(8):878-884. PubMed ID: 28199174
[TBL] [Abstract][Full Text] [Related]
15. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
Fallah-Rad N; Walker JR; Wassef A; Lytwyn M; Bohonis S; Fang T; Tian G; Kirkpatrick ID; Singal PK; Krahn M; Grenier D; Jassal DS
J Am Coll Cardiol; 2011 May; 57(22):2263-70. PubMed ID: 21616287
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer.
Thavendiranathan P; Shalmon T; Fan CS; Houbois C; Amir E; Thevakumaran Y; Somerset E; Malowany JM; Urzua-Fresno C; Yip P; McIntosh C; Sussman MS; Brezden-Masley C; Yan AT; Koch CA; Spiller N; Abdel-Qadir H; Power C; Hanneman K; Wintersperger BJ
JAMA Cardiol; 2023 Jun; 8(6):524-534. PubMed ID: 37043251
[TBL] [Abstract][Full Text] [Related]
17. 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab.
Bouwer NI; Liesting C; Kofflard MJM; Brugts JJ; Kock MCJ; Kitzen JJEM; Levin MD; Boersma E
Cardiovasc Ultrasound; 2021 Nov; 19(1):35. PubMed ID: 34753503
[TBL] [Abstract][Full Text] [Related]
18. Comparing left ventricular ejection fraction measurement using cardiovascular magnetic resonance imaging.
Luk WH; Au-Yeung AW; Lo AX; Loke TK; Ng TW
Radiol Technol; 2014; 85(5):494-9. PubMed ID: 24806052
[TBL] [Abstract][Full Text] [Related]
19. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients.
Blancas I; Martín-Pérez FJ; Garrido JM; Rodríguez-Serrano F
Breast; 2020 Dec; 54():106-113. PubMed ID: 32977298
[TBL] [Abstract][Full Text] [Related]
20. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity.
Lambert J; Lamacie M; Thampinathan B; Altaha MA; Esmaeilzadeh M; Nolan M; Fresno CU; Somerset E; Amir E; Marwick TH; Wintersperger BJ; Thavendiranathan P
Heart; 2020 Jun; 106(11):817-823. PubMed ID: 32098808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
